Understanding the Debate: Dose Escalation for Somatostatin Analogs in GEP-NETs Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) present a heterogeneous landscape, with treatment aims centered on controlling tumor growth, managing symptoms, and preserving quality of life. Somatostatin analogs (SSAs), such as octreotide and lanreotide, have long been foundational therapies due to their ability to curb hormonal symptoms and…